Keywords
Drug coated balloon
Target lesion revascularization
Target vessel thrombosis
How to Cite
Abstract
Introduction:
Coronary artery disease is one of the leading causes of death worldwide for which various therapeutic interventions have been proposed. The use of drug-coated balloons (DCBs). DCBs have gained attention as a promising tool for the treatment of large coronary artery disease. This study aims to see the efficacy and clinical outcomes of DCB therapy in large coronary artery disease.
Methods:
This prospective observational study involving 60 patients of CAD, was conducted in the Department of Cardiology, Rawalpindi Institute of Cardiology, Rawalpindi. The patients with large coronary artery disease were included and treated with DCB therapy. The effectiveness of DCB as the primary outcome in terms of target lesion revascularization was observed over time. Similarly secondary (adverse outcomes) were also assessed and represented as frequencies and percentages. Analysis was done by SPSS.V.26.
Results:
In our study, the mean age was 55.217±9.814 and the mean diameter of the target vessel was 3.1 ± 0.249 mm while that of the lesions was 25.25 ± 8.1 mm. On follow-up, target lesion revascularization was noted in only 8 (13.3 %), similarly, the adverse outcomes like MI in 4 (6.7%), target vessel thrombosis in 5 (8.3%), dyspnea in 8 (13.3%), effort angina in 10 (16.7%), and death was reported in just 2 (3.3%) of the patients.
Conclusion:
The use of DCB therapy resulted in a significant reduction in the proportion of patients requiring target lesion revascularization, which was the primary outcome measure. Furthermore, the secondary (adverse) outcomes exhibited a notable decrease in patients who received DCB therapy, thus demonstrating the efficacy of DCB therapy in individuals with large coronary artery disease.
References
World Health Organization. Cardiovascular diseases (CVDs) [Internet]. Geneva: WHO; [cited 2025 Mar 20]. Available from: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)
Lu K, Ye X, Chen Y, Wang P, Gong M, Xuan B, et al. Research progress of drug-eluting balloon in arterial circulatory system. Front Cardiovasc Med. 2024;11:1287852. https://doi.org/10.3389/fcvm.2024.1287852.
Nakamura H, Ishikawa T, Mizutani Y, Yamada K, Ukaji T, Kondo Y, et al. Clinical and angiographic outcomes of elective paclitaxel-coated balloon angioplasty in comparison with drug-eluting stents for de novo coronary lesions in large vessels. Int Heart J. 2023;64(2):145-153. https://doi.org/10.1536/ihj.22-498.
Felbel D, Bozic F, Mayer B, Krohn-Grimberghe M, Paukovitsch M, d'Almeida S, et al. Drug-coated balloon: an effective alternative to stent strategy in small-vessel coronary artery disease—a meta-analysis. Front Cardiovasc Med. 2023;10:1213992. https://doi.org/10.3389/fcvm.2023.1213992.
Lu K, Ye X, Chen Y, Wang P, Gong M, Xuan B, et al. Research progress of drug-eluting balloon in arterial circulatory system. Front Cardiovasc Med. 2024;11:1287852. https://doi.org/10.3389/fcvm.2024.1287852.
Rosenberg M, Waliszewski M, Krackhardt F, Chin K, Wan Ahmad WA, Caramanno G, et al. Drug-coated balloon-only strategy in de novo lesions of large coronary vessels. J Interv Cardiol. 2019;2019:6548696. https://doi.org/10.1155/2019/6548696 .
. Gitto M, Sticchi A, Chiarito M, Novelli L, Leone PP, Mincione G, et al. Drug-coated balloon angioplasty for de novo lesions on the left anterior descending artery. Circ Cardiovasc Interv. 2023 Dec;16(12):e013232. https://doi.org/10.1161/circinterventions.123.013232.
Yamada K, Ishikawa T, Nakamura H, Mizutani Y, Ukaji T, Shimura M, et al. Midterm safety and efficacy of elective drug-coated balloon angioplasty in comparison to drug-eluting stents for unrestrictive de novo coronary lesions: A single-center retrospective study. J Cardiol. 2023 Jun;81(6):537-543. https://doi.org/10.1016/j.jjcc.2022.11.014.
Zhang Y, Chen D, Dong Q, Xu Y, Fang J, Zhang H, et al. Drug-coated balloons for acute myocardial infarction: A meta-analysis of randomized clinical trials. J Interv Cardiol. 2022 Dec 27;2022:4018771. https://doi.org/10.1155/2022/4018771.
Räsänen A, Kärkkäinen JM, Eranti A, Eränen J, Rissanen TT. Percutaneous coronary intervention with drug-coated balloon-only strategy combined with single antiplatelet treatment in patients at high bleeding risk: Single-center experience of a novel concept. Catheter Cardiovasc Interv. 2023 Feb;101(3):569-578.https://doi.org/10.1002/ccd.30558.
Sanz Sánchez J, Chiarito M, Cortese B, Moretti A, Pagnotta P, Reimers B, et al. Drug-coated balloons vs drug-eluting stents for the treatment of small coronary artery disease: A meta-analysis of randomized trials. Catheter Cardiovasc Interv. 2021 Jul 1;98(1):66-75. https://doi.org/10.1002/ccd.29111.
. Wu X, Li L, He L. Drug-coated balloon versus drug-eluting stent in patients with small-vessel coronary artery disease: A meta-analysis of randomized controlled trials. Cardiol Res Pract. 2021 Apr 13;2021:1647635. https://doi.org/10.1155/2021/1647635.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Copyright (c) 2025 Saleha Haroon, Hafsa Shahid, Asim Javed , Tanveer Ahmed Raja , Naveed Pirzada, Abdur Rehman